Precigen Inc. (PGEN)

NASDAQ: PGEN · Real-Time Price · USD

1.57

0.02 (1.29%)

At close: May 02, 2025, 3:59 PM

1.62

2.83%

After-hours: May 02, 2025, 04:41 PM EDT

1.29% (1D)

Bid	1.52
Market Cap	464.88M
Revenue (ttm)	3.92M
Net Income (ttm)	-126.23M
EPS (ttm)	-0.47
PE Ratio (ttm)	-3.35
Forward PE	51.67
Analyst	Buy

Ask	1.69
Volume	930,541
Avg. Volume (20D)	1,684,500
Open	1.59
Previous Close	1.55
Day's Range	1.55 - 1.66
52-Week Range	0.65 - 2.17
Beta	1.70

About PGEN

Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic comp...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Aug 8, 2013

Employees 143

Stock Exchange NASDAQ

Ticker Symbol PGEN

Website https://www.precigen.com

Full Company Profile

Analyst Forecast

According to 5 analyst ratings, the average rating for PGEN stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 280.95% from the latest price.

Stock Forecasts

Next Earnings Release

Precigen Inc. is scheduled to release its earnings on May 13, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 months ago

+18.58%

Precigen shares are trading higher after HC Wainwr... Unlock content with Pro Subscription

4 months ago

+28.47%

Precigen shares are trading higher after the company announced it's seeking FDA priority review for its gene therapy targeting rare respiratory disease.

News

1 month ago · seekingalpha.com

Precigen, Inc. (PGEN) Q4 2024 Earnings Call Transcript

Precigen, Inc. (NASDAQ:PGEN ) Q4 2024 Earnings Conference Call March 19, 2025 4:30 PM ET Company Participants Steven Harasym - IR Helen Sabzevari - President and CEO Rutul Shah - COO Phil Tennant - CC...

1 month ago · zacks.com

Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates

Precigen, Inc. (PGEN) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.09 per share a year ago.

2 months ago · seekingalpha.com

Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement

BLA of PRGN-2012 for patients with Recurrent Respiratory Papillomatosis was accepted by FDA with a Priority Review date of August 27th of 2025. Marketing approval of PRGN-2012 for RRP would be huge be...

2 months ago · zacks.com

Precigen, Inc. (PGEN) Just Flashed Golden Cross Signal: Do You Buy?

Precigen, Inc. (PGEN) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, PGEN's 50-day simple moving average crossed above its 2...